More than 40% of Americans are obese, according to the Centers for Disease Control and Prevention (CDC). And the epidemic isn ...

GLP-1 receptor agonists semaglutide and tirzepatide are associated with reduced risks of dementia, stroke, and mortality in adults with type 2 diabetes and obesity, new data show.

Binge eating disorder is strongly associated with weight gain and obesity, though not all individuals with obesity have BED.

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

Connecticut passed a new law last week in an effort to lower its spending on weight-loss drugs for its state insurance program — HUSKY Health, which includes Medicaid and CHIP enrollees — and it could ...

A new study suggests that drugs like Ozempic and Mounjaro may reduce dementia risk. Researchers at the University of Galway ...

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

SHOPPING: Take charge of your health with help from Hims, the weight loss program that puts your specific needs front and ...

First Kellogg, then Kraft Heinz. Call it the anti-gestalt effect: the whole of a company can be worth less than its sum of ...

Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.

Polycystic Ovary Syndrome or PCOS affects millions of women in the United States. There is currently no standard treatment for it. Weight loss drugs like semaglutide are now showing positive results.

A study reveals potentially fatal side effects of GLP-1 drugs, that people are using to lose weight. It’s well known that ...